Article Versions Notes

Diep L, Barbier V, Doussière M, Touboul E, Jesson C, Deprez V, Sobhy-Danial J-M, Fardellone P, Goëb V. Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates. Journal of Clinical Medicine. 2022; 11(20):5978. https://doi.org/10.3390/jcm11205978

Diep, Laetitia, Vincent Barbier, Marie Doussière, Estelle Touboul, Claire Jesson, Valentine Deprez, Jean-Marc Sobhy-Danial, Patrice Fardellone, and Vincent Goëb. 2022. "Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates" Journal of Clinical Medicine 11, no. 20: 5978. https://doi.org/10.3390/jcm11205978

Diep, L., Barbier, V., Doussière, M., Touboul, E., Jesson, C., Deprez, V., Sobhy-Danial, J.-M., Fardellone, P., & Goëb, V. (2022). Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates. Journal of Clinical Medicine, 11(20), 5978. https://doi.org/10.3390/jcm11205978